Nirmatrelvir and Ritonavir side effects: what 53,818 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Paxlovid
Who reports
53,818 reports · 18% serious · 557 with death outcome · 65% female
Used for
PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID which includes nirmatrelvir, a severe acute .
What it is
PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. Nirmatrelvir is a SARS-CoV-2 main protease (M pro ) inhibitor, and ritonavir is an HIV-1 protease inhibitor and CYP3A inhibitor. Nirmatrelvir
Boxed warning
SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID • PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events [see Contraindications (4) , Warnings and Precautions (5.1) , and Drug Interactions (7) ].
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,006 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Disease recurrence | 20,103 | 285.7 281.1–290.3ROR 455.4 · calibrated p 1e-13 ✓ | 164.1 EB05 162.2 · IC025 +7.3 3/3 methods agree | Reporting / coding artifact | serious PRR 43.3 · 80% consumer | not reported in cached trials |
| Asymptomatic covid-19 | 70 | 83.1 64.2–107.6ROR 83.2 · calibrated p 7e-7 ✓ | 67.3 EB05 55.1 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=4 · ♀ 43% (drug 65%) · 86% consumer | not reported in cached trials |
| Symptom recurrence | 994 | 79.5 74.3–85.1ROR 81.0 · calibrated p 5e-7 ✓ | 65.9 EB05 62.6 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious n=71 · 77% consumer | not reported in cached trials |
| Covid-19 | 22,815 | 57.6 57.0–58.3ROR 99.3 · calibrated p 1e-7 ✓ | 50.2 EB05 49.7 · IC025 +5.6 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 24.2 · 78% consumer | not reported in cached trials |
| Sars-cov-2 test negative | 73 | 46.5 36.5–59.3ROR 46.6 · calibrated p 3e-5 ✓ | 41.2 EB05 33.8 · IC025 +4.6 3/3 methods agree | Reporting / coding artifact | serious n=37 · 86% consumer | not reported in cached trials |
| Dysgeusia (altered taste) | 7,348 | 42.5 41.5–43.4ROR 49.0 · calibrated p 2e-5 ✓ | 38.3 EB05 37.6 · IC025 +5.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 39.5 · 81% consumer | NCT05263908: 189/2,829 (6.7%) on Nirmatrelvir and Ritonavir |
| Contraindicated product prescribed | 129 | 32.5 27.2–38.9ROR 32.6 · calibrated p 2e-4 ✓ | 30.0 EB05 25.9 · IC025 +4.5 3/3 methods agree | Reporting / coding artifact | serious n=6 · ♀ 43% (drug 65%) | not reported in cached trials |
| Post-acute covid-19 syndrome | 84 | 28.4 22.7–35.4ROR 28.4 · calibrated p 4e-4 ✓ | 26.3 EB05 21.9 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=28 · 79% consumer | not reported in cached trials |
| Immunosuppressant drug level increased | 189 | 23.7 20.4–27.4ROR 23.7 · calibrated p 9e-4 ✓ | 22.3 EB05 19.8 · IC025 +4.2 3/3 methods agree | Lab value / disease marker | serious n=179 · ♀ 41% (drug 65%) | not reported in cached trials |
| Taste disorder | 1,045 | 21.4 20.1–22.8ROR 21.8 · calibrated p 0.001 ✓ | 20.3 EB05 19.3 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious PRR 25.2 · 79% consumer | NCT05263908: 48/2,829 (1.7%) on Nirmatrelvir and Ritonavir |
| Product dose confusion | 17 | 20.5 12.6–33.4ROR 20.5 · calibrated p 0.003 ✓ | 19.0 EB05 12.3 · IC025 +2.9 3/3 methods agree | Reporting / coding artifact | – | not reported in cached trials |
| Sars-cov-2 test positive | 629 | 19.2 17.7–20.8ROR 19.4 · calibrated p 0.002 ✓ | 18.3 EB05 17.2 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=275 · 76% consumer | not reported in cached trials |
| Upper respiratory tract congestion | 135 | 18.8 15.9–22.4ROR 18.9 · calibrated p 0.003 ✓ | 18.0 EB05 15.6 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=9 · 86% consumer | not reported in cached trials |
| Product taste abnormal | 566 | 17.1 15.7–18.6ROR 17.3 · calibrated p 0.004 ✓ | 16.4 EB05 15.3 · IC025 +3.9 3/3 methods agree | Reporting / coding artifact | serious n=58 · 83% consumer | not reported in cached trials |
| Product prescribing error | 968 | 16.6 15.5–17.7ROR 16.9 · calibrated p 0.004 ✓ | 15.9 EB05 15.1 · IC025 +3.9 3/3 methods agree | Reporting / coding artifact | serious PRR 7.5 | not reported in cached trials |
| Product blister packaging issue | 39 | 15.3 11.1–21.1ROR 15.3 · calibrated p 0.008 ✓ | 14.6 EB05 11.0 · IC025 +3.1 3/3 methods agree | Reporting / coding artifact | 71% consumer | not reported in cached trials |
| Incorrect product administration duration | 736 | 14.6 13.6–15.7ROR 14.8 · calibrated p 0.007 ✓ | 14.1 EB05 13.3 · IC025 +3.7 3/3 methods agree | Reporting / coding artifact | serious n=105 | not reported in cached trials |
| Intercepted product prescribing error | 44 | 13.7 10.1–18.5ROR 13.7 · calibrated p 0.012 ✓ | 13.0 EB05 9.9 · IC025 +3.0 3/3 methods agree | Labeled (related wording) related wording | – | not reported in cached trials |
| Product after taste | 29 | 12.4 8.6–18.0ROR 12.4 · calibrated p 0.018 ✓ | 11.5 EB05 8.1 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | serious n=5 · 86% consumer | not reported in cached trials |
| Coronavirus test positive | 32 | 12.3 8.7–17.5ROR 12.3 · calibrated p 0.018 ✓ | 11.5 EB05 8.3 · IC025 +2.8 3/3 methods agree | Lab value / disease marker | serious n=14 · 91% consumer | not reported in cached trials |
| Faeces pale | 67 | 12.1 9.5–15.5ROR 12.1 · calibrated p 0.018 ✓ | 11.6 EB05 9.3 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=19 · 79% consumer | not reported in cached trials |
| Rebound effect | 342 | 12.1 10.9–13.5ROR 12.2 · calibrated p 0.016 ✓ | 11.7 EB05 10.7 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 33.2 | not reported in cached trials |
| Product size issue | 145 | 10.9 9.2–12.9ROR 10.9 · calibrated p 0.025 ✓ | 10.5 EB05 9.1 · IC025 +3.1 3/3 methods agree | Reporting / coding artifact | serious n=32 | not reported in cached trials |
| Labelled drug-drug interaction issue | 38 | 10.8 7.8–14.9ROR 10.8 · calibrated p 0.028 ✓ | 10.0 EB05 7.5 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | serious n=26 · ♀ 44% (drug 65%) | not reported in cached trials |
| Tongue erythema | 21 | 10.3 6.7–15.9ROR 10.3 · calibrated p 0.037 ✓ | 9.1 EB05 6.0 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | serious n=7 · 81% consumer | not reported in cached trials |
| Product packaging confusion | 59 | 9.7 7.5–12.5ROR 9.7 · calibrated p 0.039 ✓ | 9.1 EB05 7.2 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | serious n=5 | not reported in cached trials |
| Nasal congestion (stuffy nose) | 1,367 | 9.3 8.8–9.8ROR 9.5 · calibrated p 0.038 ✓ | 9.1 EB05 8.7 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 7.6 · 82% consumer | not reported in cached trials |
| Tongue coated | 39 | 9.0 6.5–12.3ROR 9.0 · calibrated p 0.051 | 8.3 EB05 6.2 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious n=6 · ♀ 85% (drug 65%) · 82% consumer | not reported in cached trials |
| Contraindicated product administered | 674 | 8.9 8.2–9.6ROR 9.0 · calibrated p 0.046 ✓ | 8.7 EB05 8.1 · IC025 +3.0 3/3 methods agree | Reporting / coding artifact | serious PRR 7.0 | not reported in cached trials |
| Sneezing | 478 | 8.5 7.8–9.3ROR 8.6 · calibrated p 0.054 | 8.3 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious PRR 6.7 · 85% consumer | not reported in cached trials |
| Sinus pain | 48 | 8.3 6.2–11.0ROR 8.3 · calibrated p 0.065 | 7.7 EB05 6.0 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious n=9 · 87% consumer | not reported in cached trials |
| Prescription drug used without a prescription | 127 | 8.3 6.9–9.8ROR 8.3 · calibrated p 0.062 | 7.9 EB05 6.8 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=5 · 87% consumer | not reported in cached trials |
| Paranasal sinus discomfort | 70 | 7.4 5.8–9.3ROR 7.4 · calibrated p 0.089 | 7.0 EB05 5.7 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious n=11 · 81% consumer | not reported in cached trials |
| Product confusion | 14 | 7.1 4.2–12.1ROR 7.1 · calibrated p 0.116 | 5.9 EB05 3.7 · IC025 +1.6 3/3 methods agree | Reporting / coding artifact | – | not reported in cached trials |
| Rhinorrhoea (runny nose) | 1,090 | 6.7 6.3–7.1ROR 6.8 · calibrated p 0.107 | 6.6 EB05 6.3 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious PRR 5.1 · 82% consumer | not reported in cached trials |
| Product use complaint | 253 | 6.4 5.7–7.3ROR 6.5 · calibrated p 0.124 | 6.3 EB05 5.7 · IC025 +2.4 3/3 methods agree | Reporting / coding artifact | serious n=35 | not reported in cached trials |
| Suspected off label use | 28 | 6.4 4.4–9.3ROR 6.4 · calibrated p 0.141 | 5.7 EB05 4.2 · IC025 +1.9 3/3 methods agree | Labeled (related wording) related wording | 100% clinician | not reported in cached trials |
| Anosmia (loss of smell) | 230 | 6.3 5.5–7.1ROR 6.3 · calibrated p 0.134 | 6.1 EB05 5.5 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious n=54 · 84% consumer | not reported in cached trials |
| Therapeutic product effect incomplete | 1,080 | 6.0 5.7–6.4ROR 6.1 · calibrated p 0.142 | 5.9 EB05 5.6 · IC025 +2.5 3/3 methods agree | Reporting / coding artifact | serious PRR 4.2 · 81% consumer | not reported in cached trials |
| Product expiration date issue | 21 | 6.0 3.9–9.3ROR 6.0 · calibrated p 0.167 | 5.3 EB05 3.7 · IC025 +1.7 3/3 methods agree | Reporting / coding artifact | – | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Nirmatrelvir and Ritonavir as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (2 of 40 signal terms matched).
- NCT05263908 — A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19 (N=3346, phase n/a; 84 AE terms posted; arms: Paxlovid PACK (Nirmatrelvir/Ritonavir))
- NCT06291831 — A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. (N=3011, phase n/a; 16 AE terms posted; arms: Treated With Paxlovid; Not Treated With Paxlovid)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Covid-19 | 22,815 | 57.6 57.0–58.3ROR 99.3 · calibrated p 1e-7 ✓ | 50.2 EB05 49.7 · IC025 +5.6 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 24.2 · 78% consumer | not reported in cached trials |
| Disease recurrence | 20,103 | 285.7 281.1–290.3ROR 455.4 · calibrated p 1e-13 ✓ | 164.1 EB05 162.2 · IC025 +7.3 3/3 methods agree | Reporting / coding artifact | serious PRR 43.3 · 80% consumer | not reported in cached trials |
| Dysgeusia (altered taste) | 7,348 | 42.5 41.5–43.4ROR 49.0 · calibrated p 2e-5 ✓ | 38.3 EB05 37.6 · IC025 +5.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 39.5 · 81% consumer | NCT05263908: 189/2,829 (6.7%) on Nirmatrelvir and Ritonavir |
| Diarrhoea (diarrhea) | 4,027 | 2.4 2.4–2.5ROR 2.6 · calibrated p 0.786 | 2.4 EB05 2.4 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.7 · 77% consumer | NCT05263908: 92/2,829 (3.3%) on Nirmatrelvir and Ritonavir |
| Nausea | 2,636 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.520 | 1.3 EB05 1.3 · IC025 +0.3 | Labeled adverse reaction exact term | serious PRR 2.4 · 73% consumer | NCT05263908: 2/2,829 (0.1%) on Nirmatrelvir and Ritonavir (serious AE) |
| Headache | 2,178 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.556 | 1.4 EB05 1.3 · IC025 +0.4 | Labeled adverse reaction exact term | serious PRR 2.1 · 80% consumer | NCT05263908: 6/2,829 (0.2%) on Nirmatrelvir and Ritonavir |
| Cough | 2,048 | 2.9 2.7–3.0ROR 2.9 · calibrated p 0.646 | 2.9 EB05 2.7 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | serious PRR 2.6 · 81% consumer | NCT05263908: 5/2,829 (0.2%) on Nirmatrelvir and Ritonavir |
| Fatigue (tiredness) | 2,014 | 1.0 1.0–1.1ROR 1.0 · calibrated p 0.313 | 1.0 EB05 1.0 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Not in label — unassessed | serious PRR 1.6 · 79% consumer | NCT06291831: 4/2,005 (0.2%) on Nirmatrelvir and Ritonavir |
| Incorrect dose administered | 1,717 | 3.0 2.9–3.1ROR 3.1 · calibrated p 0.609 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | Reporting / coding artifact | serious PRR 3.5 | not reported in cached trials |
| Vomiting | 1,408 | 1.2 1.1–1.2ROR 1.2 · calibrated p 0.423 | 1.2 EB05 1.1 · IC025 +0.1 | Labeled adverse reaction exact term | serious PRR 2.3 | NCT05263908: 1/2,829 (0.0%) on Nirmatrelvir and Ritonavir (serious AE) |
| Malaise (feeling unwell) | 1,375 | 1.2 1.2–1.3ROR 1.2 · calibrated p 0.457 | 1.2 EB05 1.2 · IC025 +0.2 | Labeled adverse reaction exact term | serious PRR 1.5 · 85% consumer | NCT05263908: 12/2,829 (0.4%) on Nirmatrelvir and Ritonavir |
| Nasal congestion (stuffy nose) | 1,367 | 9.3 8.8–9.8ROR 9.5 · calibrated p 0.038 ✓ | 9.1 EB05 8.7 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 7.6 · 82% consumer | not reported in cached trials |
| Off label use (used outside approved label) | 1,323 | 0.6 0.6–0.6ROR 0.6 · calibrated p 0.078 | 0.6 EB05 0.6 · IC025 -0.8 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 1.3 | not reported in cached trials |
| Drug interaction | 1,299 | 3.2 3.0–3.4ROR 3.3 · calibrated p 0.547 | 3.2 EB05 3.0 · IC025 +1.6 3/3 methods agree | Reporting / coding artifact | serious PRR 9.1 | not reported in cached trials |
| Pyrexia (fever) | 1,255 | 1.4 1.3–1.5ROR 1.4 · calibrated p 0.591 | 1.4 EB05 1.3 · IC025 +0.4 | Not in label — unassessed | serious PRR 1.1 · 79% consumer | NCT05263908: 2/2,829 (0.1%) on Nirmatrelvir and Ritonavir (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Asymptomatic covid-19 — n=70, PRR 83.1
- Symptom recurrence — n=994, PRR 79.5
- Post-acute covid-19 syndrome — n=84, PRR 28.4
- Taste disorder — n=1,045, PRR 21.4 (also seen in trial arm)
- Upper respiratory tract congestion — n=135, PRR 18.8
- Faeces pale — n=67, PRR 12.1
- Rebound effect — n=342, PRR 12.1
- Tongue erythema — n=21, PRR 10.3
- Nasal congestion — n=1,367, PRR 9.3
- Tongue coated — n=39, PRR 9.0
✓ A hand-written Bradford Hill causality assessment exists for this drug: Nirmatrelvir/ritonavir (Paxlovid) ↔ COVID-19 recurrence ("Paxlovid rebound").
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Nirmatrelvir and Ritonavir?
In FDA FAERS, the most frequently co-reported reaction terms for Nirmatrelvir and Ritonavir are covid-19, dysgeusia, diarrhoea, nausea, headache, cough. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Nirmatrelvir and Ritonavir have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID • PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events [see Contraindications (4) , Warnings and Precautions (5.1) , and Drug Interactions (7) ].
Do FAERS signals prove that Nirmatrelvir and Ritonavir causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a, effective 20260219; matched on
openfda.generic_name.exact:"NIRMATRELVIR AND RITONAVIR") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,046 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
NIRMATRELVIR, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.